Each year, the United Nations Office on Drugs and Crime (UNODC) publishes the World Drug Report, one of the most widely referenced global assessments of illicit drug markets, production, trafficking, and patterns of drug use. The 2025 edition of the report provides updated analysis of global drug trends and their implications for governments, public health systems, and employers operating in safety-critical environments. Readers who wish to explore the original research can access the World Drug Report 2025 overview and supporting materials directly from UNODC, including the official key findings summary and the accompanying key findings report booklet. This article summarises the key insights from the World Drug Report 2025 and explains their implications for workplace drug and alcohol policies. It also explores why fingerprint drug testing offers a practical and modern response to the evolving risks highlighted in the report.
Why This Report Matters to Employers
The World Drug Report 2025 outlines three critical employer-relevant risks:
- More drug use globally increases the likelihood of workforce exposure.
- Cocaine and stimulants continue to expand.
- Treatment gaps remain significant, which reinforces the need to pair accountability with support.
Employers in safety-critical environments carry a duty of care to employees, contractors, and the public. When drug use rises, the likelihood of impairment-related risk increases. Regulators and investigators often ask whether employers had reasonable, proportionate controls in place to prevent foreseeable harm. A current, well-governed workplace drug and alcohol policy is one of the clearest ways to demonstrate that an organisation takes risk management seriously.
Big Takeaway 1: Global Drug Use is at Record Levels
UNODC estimates that approximately 316 million people aged 15 to 64 used drugs in 2023, representing around six percent of the global population in that age group. UNODC reports that this is the highest figure recorded to date. Cannabis remains the most widely used drug globally. The report also highlights significant use of opioids, cocaine, amphetamines, and other synthetic substances.
What This Means for Employers
Workforces reflect society. As prevalence rises, employers should expect workplace exposure to increase, including in roles where impairment poses an immediate risk. This does not mean most employees use drugs, and it does not justify heavy-handed approaches. It means employers should treat workplace drug risk as a normal part of safety management, alongside fatigue risk, vehicle safety, and other workplace hazards that can affect an employee’s ability to perform their duties safely.
A practical implication follows: Employers should regularly review policies and testing strategies, as historical assumptions about prevalence and drug types may no longer reflect reality.
If you want a practical, employer-focused framework, our guide provides an overview of how to structure a robust programme.
Big Takeaway 2: Cocaine and Stimulants Continue to Expand
The World Drug Report 2025 highlights record cocaine production and evolving trafficking routes, with associated increases in availability and seizures in multiple regions.
What This Means for Employers
Stimulants create specific workplace hazards because they can affect judgment, attention, and risk-taking behaviour. In safety-critical settings, stimulants can contribute to:
- Reduced situational awareness
- Increased risk and damages
- Poor decision-making
- Fatigue effects during the comedown
These risks can be potentially fatal in roles involving vehicles, machinery, working at height, hazardous substances, and complex procedural tasks. The policy implication is straightforward. Employers should ensure their testing panel and governance model reflect current stimulant risk. Managers should understand when to apply reasonable suspicion or post-incident testing. Policies with vague language or inconsistent enforcement can create legal and cultural problems while failing to reduce risk. For employers seeking a practical framework, this guide outlines how organisations can design consistent and defensible testing programmes for safety-critical industries.
Big Takeaway 3: Employees Battling Addiction Need Support
The report highlights a persistent gap between the number of people who would benefit from treatment and the number who receive adequate support. Employers are not healthcare providers, but workplace policies often influence whether employees seek help early or delay seeking help until it becomes an incident.
What This Means for Employers
A modern workplace drug and alcohol policy should combine clear testing procedures, fair and consistent enforcement, proportionate disciplinary frameworks, and access to support or referral pathways where appropriate. Testing is more than detection. It establishes an environment where safety, accountability, and well-being meet.
In practical terms, employers can support employees in two concrete ways.
- Build a formal referral pathway into the policy by specifying each step the employer must take when referring an employee to confidential support, such as an Employee Assistance Programme, occupational health, or external substance misuse services. Clearly define, in plain language, which events or behaviours will trigger a referral.
- Implement a structured return-to-work framework by documenting improvement plans, conducting appropriate follow-up testing, and providing managers with specific guidance on supporting rehabilitation and ensuring safety requirements are met. For organisations developing or reviewing their approach, this guide on how to introduce workplace drug testing provides practical advice on balancing safety, fairness, and employee support.
A Practical Response for Employers: Fingerprint Drug Testing
The World Drug Report 2025 findings reinforce a clear message for employers. Drug markets are expanding, stimulant availability is increasing, and treatment gaps remain significant. For organisations operating in safety-critical environments, these trends increase the importance of having a workplace drug and alcohol policy that is practical, consistent, and capable of identifying impairment-related risk.
Intelligent Fingerprinting provides employers with a modern, non-invasive approach to workplace drug screening that aligns with these challenges. Our fingerprint drug testing solution uses sweat from the fingertips to detect recent drug use, enabling organisations to implement rapid, on-site testing without the operational disruption or privacy concerns often associated with traditional methods. The technology is designed to support the very governance principles discussed throughout this article: consistent testing procedures, proportionate enforcement, and a focus on recent impairment rather than historic lifestyle behaviour.
For employers exploring how this approach works in practice, you can learn more about the fingerprint drug testing solution, review our guide to implementing fingerprint drug testing in the workplace, or watch a short demonstration of the testing process. If your organisation has not reviewed its workplace drug and alcohol policy recently, now is the right time. Assess whether your current testing programme reflects evolving drug risks and supports a fair, defensible safety framework. If you would like to see how fingerprint drug testing could strengthen your policy and operational approach, schedule a demonstration with our team and see the system in action.
